Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Unearthing EGFR Mutations and the Rewards of Persistence in Precision Oncology: Breaching the 10-Year Survival Barrier in Metastatic NSCLC With Active Disease.

JCO global oncology - 1 Feb 2020

Singh Pawan Kumar, Kumar Rajender, Bal Amanjit, Gupta Nalini, Kapoor Rakesh, Prasad Kuruswamy Thurai, Singh Navneet

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to ErbB Receptors
Share to Lung Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Precision Medicine

Share to Survival Rate

Source

Open in PubMed Open full text

Identifiers

PMID: 32031456
DOI: 10.1200/JGO.19.00357
PMCID: PMC6998025

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Unearthing EGFR Mutations and the Rewards of Persistence in Precision Oncology: Breaching the 10-Year Survival Barrier in Metastatic NSCLC With Active Disease.PMID 32031456Read ↗

EGFR pharmacogenomics: the story continues to mutate and evolve.Semantic proximity Read ↗

Searching for the Holy Grail of oncology.Semantic proximity Read ↗

Optimising therapy for EGFR-addicted NSCLC: just the start.Semantic proximity Read ↗

EGFR testing in lung cancer is ready for prime time.Semantic proximity Read ↗

Crossing the rubicon in lung adenocarcinoma: the conundrum of EGFR tyrosine kinase mutations.Semantic proximity Read ↗

Brave-ish New World--What's Needed to Make Precision Oncology a Practical Reality.Semantic proximity Read ↗

Persistence is key: Refining immunotherapy response prediction.Semantic proximity Read ↗

Making the right calls in precision oncology.Semantic proximity Read ↗

Precision projections of the delay of resistance mutations in non-small cell lung cancer via suppression of APOBECSemantic proximity Read ↗

Challenging Standard-of-Care Paradigms in the Precision Oncology EraSemantic proximity Read ↗

ctDNA guides anti-EGFR rechallenge.Semantic proximity Read ↗

Persistent mutations render cancer cells susceptible to immunotherapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.